Rappta Therapeutics, a developer of anti-cancer drugs, has raised 9 million euros in Series A financing. Novartis Venture Fund and Novo Holdings led the round with participation from other backers that included Advent Life Sciences.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: